Citations 1
Humoral immune response and safety of SARS‐CoV‐2 vaccination in very early onset inflammatory bowel disease
Kastl, Arthur , Weaver, Kimberly N. , Zhang, Xian , Strople, Jennifer A., Adler, Jeremy, Kelsen, Judith R. , Dubinsky, Marla C. , Bousvaros, Athos, Watkins, Runa , Dai, Colin, Cross, Raymond, Higgins, Peter , Bewtra, Meenakshi , Bellaguarda, Emanuelle, Chun, Kelly , Zikry, Michael, Bastidas, Monique , Boccieri, Margie E., Firestine, Ann M. , Long, Millie D. , Adler, Jeremy, Ungaro, Ryan C. , Farraye, Francis A. , Boccieri, Margie , Kappelman, Michael D. , Adler, J
Journal of Pediatric Gastroenterology and Nutrition | February 15, 2024 | Volume: 78 | Issue: 4 | Pages: 871-877
AbstractChildren with very early onset inflammatory bowel disease (VEO‐IBD) may respond differently to coronavirus disease 2019 (COVID‐19) immunization compared to healthy children or other patients with IBD. We recruited children with VEO‐IBD <6 years of age and younger following receipt of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) vaccine. Demographics, IBD characteristics, medication use, adverse events (AEs) and IBD exacerbations were collected. Blood draws (optional) were obtained for measurement of antireceptor binding domain (RBD) IgG antibodies following vaccination. Of 41 participants, none required emergency department visit or hospitalization due to AE, and only one experienced IBD exacerbation. Detectable antibody was present in 19/19 participants who provided blood sample; 6/7 participants (86%) had durable humoral response 12 months postvaccination. Children with VEO‐IBD experience robust humoral immune response to COVID‐19 immunization. Severe AEs were rare. These findings provide reassurance that children with VEO‐IBD respond well and safely to SARS‐CoV‐2 vaccination.